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Available online 9 July 2016Background: The Absorb bioresorbable vascular scaffold (BVS) was developed to address long-term safety issues
of metallic drug-eluting stents. However, it may be associated with an increased event risk during the ﬁrst year.
Methods: A systematic literature search was performed (in MEDLINE/PubMed, Cochrane CENTRAL, EMBASE, and
scientiﬁc meeting abstracts) to identify studies that compared BVS and cobalt-chromium durable polymer
everolimus-eluting stents (EES). For randomized clinical trials and non-randomized propensity score matched
studies that reported 1-year outcome data,ﬁxed/random-effectsmodelswere used to generate pooled estimates
of outcomes, presented as odds ratios (OR) with 95%-conﬁdence intervals (CI).
Results: The 1-year follow-up data of 6 trials with 5588 patients were analyzed. A device-oriented composite
endpoint (DOCE – cardiac death, target vessel myocardial infarction (MI), or target lesion revascularization
(TLR)) was reached by 308 BVS or EES patients (195/3253 vs. 113/2315). Meta-analysis showed that patients
who received BVS had an increased risk of MI (4.3% vs. 2.3%; OR:1.63, 95%-CI: 1.18–2.25, p b 0.01) and
deﬁnite-or-probable scaffold thrombosis (1.3% vs. 0.6%; OR:2.10, 95%-CI: 1.13–3.87, p = 0.02). However, there
was no signiﬁcant between-group difference in risk of DOCE (6.0% vs. 4.9%; OR:1.19, 95%-CI: 0.94–1.52, p =
0.16), cardiac death (0.8% vs. 0.7%; OR:1.14, 95%-CI: 0.54–2.39, p = 0.73), or TLR (2.5% vs. 2.5%; OR: 0.98, 95%-
CI:0.69–1.40, p = 0.92).
Conclusions: During the ﬁrst year of follow-up, patients treated with BVS had a higher incidence of MI and
scaffold thrombosis. The risk of DOCE was not signiﬁcantly different. As BVS may pay off later, future robust
data on long-term clinical outcome will be of paramount importance.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY 4.0 license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
Bioresorbable vascular scaffold
Biodegradable device
Everolimus-eluting stent
Scaffold thrombosis
Stent thrombosis
Percutaneous coronary intervention1. Introduction
Advancement in coronary device technology aims at reducing and
ultimately eliminating late and very late stent thrombosis (ST), continued
neointimal tissue growth with formation of neo-atherosclerosis, and
long-term caging of the coronary vessel – issues that are still relevant to
the latest generation of durable polymer drug-eluting stents (DES) [1].
The durable polymer coating of DES may account for impaired arterialability and freedom from bias of
, Medisch Spectrum Twente,
).
land Ltd. This is an open access articlhealing and incomplete endothelial covering of the metallic struts with
an increased risk of late ST.
The latest technical development is the bioresorbable vascular scaffold
(BVS) that aims at providing a ﬁnite period of vascular support after stent
implantation [2,3]. The potential advantages of BVS include the
preservation of vessel geometry, adaptive vascular remodeling, and
restoration of physiologic vasomotion, which offer the prospect of
late luminal expansion [2,4,5]. The Absorb BVS (Abbott Vascular,
Santa Clara, CA), a device that elutes the same drug as the widely
used cobalt chromium everolimus-eluting stent (EES) [6], is the ﬁrst
BVS that received the Conformite European (CE) mark of approval for
clinical use. In registries, the BVS showed clinical event rates that
were overall comparable to durable polymer DES [7–11]. Nevertheless,
safety and efﬁcacy of the BVS has not yet been fully established, and
there are concerns for a greater risk of scaffold thrombosis before the
human body has resorbed the device [12].e under the CC BY 4.0 license (http://creativecommons.org/licenses/by/4.0/).
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BVS were published; however, by themselves they do not have
sufﬁcient power to detect differences in important but relative
infrequent safety endpoints, such as cardiac death, myocardial infarc-
tion, and stent thrombosis. Therefore, in order to gain more insight
into the safety and efﬁcacy of the BVS versus EES during the ﬁrst year
from implantation, we performed a meta-analysis of studies that
compared both devices and reported 1-year clinical outcome data.
2. Methods
2.1. Search strategy and selection criteria
A systematic search of randomized controlled clinical trials (and non-randomized)
comparing Absorb BVS versus new-generation durable polymer cobalt-chromium EES
using Medline, the Cochrane Central Register of Controlled Trials (CENTRAL), Embase,
scientiﬁc sessions abstracts, and relevant websites (www.heart.org, www.cardiosource.
com, www.tctmd.com, www.clinicaltrialresults.org, www.escardio.org) was performed
according to the PRISMA guidelines [13]. Independent major search terms used included
“bioresorbable vascular scaffold” and “Absorb stents”. Minor search terms used in
combination with the major terms included “everolimus-eluting stents”, “clinical trials,
and “randomized trials” was performed to retrieve peer reviewed published articles and
presentations between January 2006 and October 2015.Fig. 1. Flow diagram of literature2.2. Inclusion and exclusion criteria
We included studies that had a randomized or a propensity score matching design,
and compared theAbsorb BVS versus durable polymer cobalt-chromiumEES.We included
only studies that reported clinical outcome data at 12-month follow-up. Included studies
provided numeric data on clinical endpoint of interest: target vessel myocardial infarction
(MI); target lesion revascularization (TLR); cardiac death; deﬁnite-or-probable scaffold/
stent thrombosis (ST). The ST criteria was based on the deﬁnition of the Academic
Research Consortium (ARC) [14].
We excluded studies if they met any of the following criteria: duplicate publication;
outcomes of interest not clearly reported or impossible to extract or calculate from the
published results; follow-up duration b12-months; single-arm studies; and studies that
compared BVS to a non-permanent polymer DES (i.e., bioabsorbable or bioresorbable
polymer DES). Fig. 1 depicts a ﬂow diagram for the selection of trials included in this
review, using the PRISMA guidelines [13].
2.3. Inclusion and exclusion criteria of selected studies
In general, patients aged 18 years and older, presenting with stable angina, unstable
angina or silent ischemia, who underwent percutaneous coronary intervention for one
or two de novo native coronary artery lesions in separate epicardial coronary vessels,
were eligible for enrollment in the ABSORB II, ABSORB Japan, ABSORB III, ABSORB China,
andABSORBExtend trial [15–19]. Patientswith acutemyocardial infarctionwere excluded
in all ABSORB trials. In addition, left ventricular ejection fraction b30%, PCI of the target
vessel during the last 12 months, and patients with a high bleeding risk were excluded.search and study selection.
Fig. 2. Funnel plot of standard error by log odds ratio A total of 6 studies was analyzed for effect size. Abbreviations: BVS: bioresorbable vascular scaffold; EES: everolimus-eluting stent.
Table 1
Trial design and characteristics.
Trial name Publication
year
Sample
size
Stent comparator Primary endpoint Trial design Clinical setting Follow-up
duration
(months)BVS EES
ABSORB II [15] 2015 501 Absorb
everolimus-eluting
bioresorbable
vascular scaffold
Xience
cobalt–chromium
stent (Abbott
Vascular)
Mean lumen diameter
change before
and after nitrate
administration at 3 years
Prospective,
randomized,
active-controlled,
single-blind,
parallel two-group,
multicenter clinical trial
Myocardial
ischemia
12
ABSORB
Japan [16]
2015 400 Absorb
everolimus-eluting
bioresorbable
vascular scaffold
XIENCE
Prime/Xpedition
cobalt–chromium
stent (Abbott
Vascular)
Target-lesion failure
(cardiac death,
target-vessel myocardial
infarction, or
ischemia-driven
target-lesion
revascularization)
Prospective,
multicentre,
randomized,
single-blind,
active-controlled
clinical trial
Myocardial
ischemia (stable
angina, unstable
angina, or
silent ischemia)
12
BVS-EXAMINATION
[20]
2015 290 Absorb
everolimus-eluting
bioresorbable
vascular scaffold
Xience V
cobalt–chromium
stent (Abbott
Vascular)
Combined DOCE,
including
cardiac death, target
vessel myocardial
reinfarction,
and target lesion
revascularization
Prospective study with
propensity-matched
data from Xience V
STEMI 12
ABSORB III [17] 2015 2008 Absorb
everolimus-eluting
bioresorbable
vascular scaffold
Xience V
cobalt–chromium
stent (Abbott
Vascular)
Target-lesion failure
(cardiac death,
target-vessel myocardial
infarction, or
ischemia-driven
target-lesion
revascularization)
Prospective,
multicentre,
randomized,
single-blind,
active-controlled
clinical trial
Myocardial
ischemia (stable
angina, unstable
angina, or silent
ischemia)
12
ABSORB
China [18]
2015 480 Absorb
everolimus-eluting
bioresorbable
vascular scaffold
Xience V
cobalt–chromium
stent (Abbott
Vascular)
In-segment Lumen loss Prospective,
randomized,
active-controlled,
open-label, multicenter
trial
Stable angina,
unstable angina,
post-infarct angina
or silent ischemia
12
ABSORB Extend
[19]
2015 1624 Absorb
everolimus-eluting
bioresorbable
vascular scaffold
Xience V
cobalt–chromium
stent (Abbott
Vascular)
Stent thrombosis, cardiac
death, MI (target and
non-target vessel), and
revascularisation rates
(TLR/TVR/all
revascularizations)
Prospective registry
with propensity
matched data from
Xience V
All-comers with
moderately
complex lesion in
up to 2 de
novo lesions in
separate
epicardial vessels
12
Abbreviations: BVS: bioresorbable vascular scaffold; EES: everolimus-eluting stent; DOCE: device-oriented composite endpoint;MI:myocardial infarction; STEMI: ST-elevationmyocardial
infarction; TLR: target lesion revascularization; TVR: target vessel revascularization.
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Table 2
Patient and lesion characteristics of included studies.
ABSORB II ABSORB Japan BVS EXAMINATION ABSORB III ABSORB China ABSORB Extend Total*
BVS EES BVS EES BVS EES BVS EES BVS EES BVS EES BVS EES difference (95%-CI) p
Age 61.5 ± 10.0 60.9 ±
010.0
67.1 ± 9.4 67.3 ± 9.6 56.01 ±
12.75
57.57 ±
12.01
63.5 ± 10.6 63.6 ± 10.3 57.2 ± 11.4 57.6 ± 9.6 61 NR 62.1 ±
10.7
61.5 ±
10.5
0.60 (−0.09 to 1.29) 0.09
Diabetes 80/332
(24%)
40/166
(24%)
96/266
(36%)
48/134
(36%)
37/290
(13%)
37/290
(13%)
416/1320
(32%)
224/686
(33%)
60/238
(25%)
55/237
(23%)
219/812
(27%)
NR 689
(28%)
404
(27%)
0.01 (−0.01 to 0.04) 0.32
Active smoking 79/335
(24%)
36/166
(22%)
53/266
(20%)
29/134
(22%)
177/290
(61%)
220/290
(76%)
281/1322
(21%)
142/686
(21%)
78/238
(33%)
84/237
(35%)
187/812
(23%)
NR 668
(27%)
511
(34%)
−0.07 (−0.09 to−0.04) b0.01
Previous MI 93/335
(28%)
48/166
(29%)
42/262
(16%)
32/134
(24%)
10/290
(4%)
10/290
(4%)
282/1311
(22%)
150/681
(22%)
40/238
(17%)
38/237
(16%)
235/812
(29%)
NR 467
(19%)
278
(18%)
0.01 (−0.02 to 0.03) 0.57
Previous PCI 14/120
(12%)
5/56 (9%) 9/266 (3%) 7/134 (5%) 10/290
(3%)
11/290
(4%)
96/1249
(8%)
38/651
(6%)
23/238
(10%)
19/237
(8%)
NR NR 152 (7%) 80 (6%) 0.01 (−0.01 to 0.03) 0.17
Unstable angina 68/335
(20%)
37/166
(22%)
26/266
(10%)
22/134
(16%)
NA NA 355/1321
(27%)
168/686
(25%)
154/238
(65%)
152/237
(64%)
219/812
(27%)
NR 603
(28%)
379
(31%)
−0.03 (−0.06 to 0.001) 0.06
Multivessel
disease
57/335
(17%)
25/166
(15%)
NR NR 24/290
(8%)
28/290
(10%)
NR NR 42/238
(18%)
51/237
(22%)
NR NR
LAD 163/364
(45%)
84/182
(46%)
127/275
(46%)
58/137
(42%)
145/290
(50%)
117/290
(40%)
617/1385
(45%)
301/713
(42%)
139/251
(55%)
132/252
(52%)
NR (45%) NR 1191
(46%)
692
(44%)
0.02 (−0.01 to 0.06) 0.12
LCX 106/364
(29%)
42/182
(23%)
63/275
(23%)
36/137(26%) 29/290
(10%)
45/290
(16%)
363/1385
(26%)
218/713
(31%)
49/251
(20%)
61/252
(24%)
NR (26%) NR 610
(24%)
402
(26%)
−0.02 (−0.04 to 0.01) 0.20
RCA 95/364
(26%)
56/182
(31%)
85/275
(31%)
43/137
(31%)
114/290
(39%)
126/290
(43%)
404/1385
(29%)
194/713
(27%)
63/251
(25%)
59/252
(23%)
NR (28%) NR 761
(30%)
478
(30%)
−0.01 (−0.04 to 0.02) 0.63
ACC/AHA lesion
class
B1 193/363
(53%)
90/180
(50%)
55/275
(20%)
28/137
(20%)
NR NR NR NR 53/251
(21%)
56/252
(22%)
NR (53%) NR
B2 159/363
(44%)
87/180
(48%)
154/275
(56%)
68/137
(50%)
120/251
(48%)
126/252
(50%)
NR (42%)
C 6/363 (2%) 2/180
(1%)
55/275
(20%)
36/137
(26%)
68/251
(27%)
55/252
(22%)
NR (3%)
Type B2/C lesion
class
165/363
(45%)
89/180
(49%)
209/275
(76%)
104/137
(76%)
NR NR 949/1381
(69%)
513/708
(73%)
241/251
(96%)
236/251
(94%)
NR (98%) NR 1564
(69%)
942
(74%)
−0.04 (−0.08 to−0.02) 0.002
Values are n (%) ormean±SD. *ABSORB Extendwas not included in “total” because no baseline datawas available for the EES group. Abbreviations: ACC:American College of Cardiology; AHA: AmericanHeart Association; BVS: bioresorbable vascular
scaffold; EES: everolimus-eluting stent; LAD: left anterior descending artery; LCX: left circumﬂex artery; MI: myocardial infarction; NA: not available; NR: not reported; PCI: percutaneous coronary intervention; RCA: right coronary artery.
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1091B.N. Mukete et al. / International Journal of Cardiology 221 (2016) 1087–1094Main angiographic exclusion criteria were left main or ostial location of the lesion, excessive
vessel tortuosity, heavy calciﬁcation proximal to or within the target lesion, and bifurcation
lesions with side branch ≥2.0 mm requiring guidewire or dilation [15–19]. The
BVS-EXAMINATION Study is an observational study, in which all consecutive STEMI
patients treated with BVS were enrolled [20].
2.4. Data extraction and assessment of bias
All publicationswere independently assessed for eligibility at the title or abstract level
by 3 independent investigators (BNM, LCvdH, KT). We collected information about the
study design, clinical and procedural characteristics, and clinical and safety outcomes.
The Cochrane Collaboration's tool was used to assess the risk of bias based on the quality of
each eligible trial [21]. In addition, we visually assessed for publication bias with a funnel
plot (Fig. 2) while the Begg and Mazumdar test [22] was used to quantify the amount of
publication bias.
2.5. Study endpoints
We assessed a device-oriented composite endpoint (DOCE–cardiac death, target vessel
myocardial infarction, or target lesion revascularization), reﬂecting efﬁcacy and safety.
Individual endpoints of efﬁcacy were TVR and TLR. Individual safety endpoints were cardiac
death, target vessel MI, and deﬁnite-or-probable ST, as deﬁned by the ARC [14].
2.6. Statistical analysis
For each clinical and combined clinical endpoint, the independent odds ratio (OR) and
weighted mean difference was calculated with the 95% conﬁdence interval (CI). A summary
ORwas then derived for the comparison of BVSwith EES. The summary effect sizewas deter-
mined using a ﬁxed/random effect model based on the absence/presence of heterogeneity
respectively. Heterogeneitywas assessed using the I2 statistic [23].We assumed heterogene-
ity among the studieswhen thedegree of inconsistency (using I2 statistics)was N50%with an
associated p-value ≤0.05. We used the Mantel–Haenszel [24] ﬁxed-effect model and
DerSimonian and Liard [25] random-effect model to calculate the summary effect size
based on the absence or presence of heterogeneity among studies. A chi-square statistic
was used to determine difference between baseline clinical and angiographic characteristics
and Unpaired two-tailed student t-test was used to calculate difference in mean of
the procedural characteristics between the two groups. We used the Comprehensive
Meta-Analysis (CMA) version 2.0 program for outcomes statistical analysis [26].
3. Results
A total of 6 studies met the inclusion criteria with a sample size of
5588 patients (3263 in the BVS arm versus 2325 in the EES arm). The
patients of the EES arm received cobalt-chromium-based stents (Xience
V, Xience Prime, or Xience Xpedition, Abbott Vascular, Santa Clara, CA,
USA) and those of the BVS group were treated with Absorb BVS. Five
(ABSORB II [15], ABSORB Japan [16], ABSORB III [17], ABSORB China
[18], and ABSORB Extend [19] out of 6 studies enrolled patientswith sta-
ble angina or silent ischemia and one study (BVS-EXAMINATION [20])
enrolled only patients with ST-elevation MI. The BVS-EXAMINATION
study included a third treatment arm that received a bare metal stent
(Multilink Vision, Abbott Vascular) but was excluded from our analysis.
Patients were on average 62.1 ± 10.7 vs. 61.5± 10.5 years old (p=
0.09) and 28% vs. 27% (p = 0.32) diabetics for BVS vs. EES group. More
than 70% of all patients were treated for ACC/AHH class B2 or C lesions.
The follow-up period was 1 year in all studies. Tables 1, 2, and 3 shows
the design of the individual studies, baseline clinical and angiographic
characteristics, and the procedural characteristics. Between the BVS
and EES groups there was no signiﬁcant difference in the proportion
of patients with diabetes, previous MI, previous PCI, presentation with
unstable angina, or in the proportion of multivessel treatment. However,
there were signiﬁcantly more active smokers (p b 0.01) and type B/C
lesions (p b 0.01) in the BVS group (Table 2). Between BVS and EES,
there was no difference in mean reference vessel diameter (2.68 ±
0.41 mm vs. 2.70 ± 0.40 mm); p = 0.16, mean lesion length (13.1 ±
5.3 mm vs. 13.4 ± 5.3 mm); p = 0.11, mean scaffold/stent length
(21.0 ± 7.5 mm vs. 21.1 ± 8.2 mm); p = 0.79 and mean scaffold/
stent diameter (3.14 ± 0.40 mm vs. 3.12 ± 0.41 mm); p = 0.12.
Between groups there was no signiﬁcant difference in pre-dilatation
minimum lumen diameter (0.96 ± 0.34 mm vs. 0.95 ± 0.30 mm; p =
0.38). However, the ﬁnal minimum lumen diameter was lower (2.36 ±
1092 B.N. Mukete et al. / International Journal of Cardiology 221 (2016) 1087–10940.36 mm vs. 2.53 ± 0.35 mm; p b 0.01) and the acute gain was higher
(1.41 ± 0.41 mm vs. 1.58 ± 0.38 mm; p b 0.01) in patients with BVS.
3.1. Efﬁcacy outcomes
Study-level outcomes after 12 months follow-up for DOCE, the indi-
vidual components of DOCE, TVR, and ST were shown in Table 4 and
Fig. 3. Follow-up was available in 3253 patients treated with BVS and in
2315 patients treated with EES. Slightly more than 80% of patients were
on dual antiplatelet therapy at 12-month follow-up.
DOCE occurred in 6.0% of the patients treated with BVS and in 4.9%
of the patients treated with EES (OR 1.19, 95%-CI: 0.94–1.52, p = 0.16;
heterogeneity: I2 = 0, Q = 1.49, df = 5; p = 0.91). The rate of cardiac
death and TLR were similar for both patients treated with BVS and EES
(OR 1.14, 95%-CI 0.54–2.39, p = 0.73 and OR 0.98, 95%-CI 0.69–1.40,
p = 0.92, respectively).
3.2. Safety outcomes
During 1-year follow-up, deﬁnite-or-probable stent thrombosis
occurred more often in the BVS-group (1.3% vs. 0.6%; OR 2.10, 95%-CI:
1.13–3.87, p = 0.02; heterogeneity: I2 = 0, Q = 1.63, df = 5, p =
0.90). In addition,more patients treatedwith BVS developed target ves-
sel MI as compared to patients treated with EES (4.3% vs. 2.3%; OR 1.63,
95%-CI: 1.18–2.25, p b 0.01; heterogeneity: I2= 0, Q=3.16, df=5, p=
0.68).
4. Discussion
The present meta-analysis shows that treatment of in patients with
obstructive coronary artery disease with the Absorb BVS was similarly
efﬁcacious as implantation of durable polymer cobalt-chromium EES
with regard to the risk of repeat revascularization (i.e. both TLR and
TVR). In addition, there was no between-group difference in cardiovas-
cular mortality. Patients who received BVS had an increased risk of MI
and deﬁnite-or-probable scaffold thrombosis. The composite endpoint
DOCE showed no signiﬁcant difference between both device groups.
The present meta-analysis differs from previous meta-analyses in
that we (1) included only trials with a minimum follow-up duration
of 12-months and (2) compared the BVS only to cobalt-chromium-
based EES. Cassese and colleagues [27] published a meta-analysis that
compared the efﬁcacy and safety outcomes in patients treated with
Absorb BVS versus EES but included two studies with 6-month follow-
up duration (TROFI II and EVERBIO II).
Despite the overall relatively small number of deﬁnite-or-probable
stent thromboses in both groups, treatment with BVS showed a signiﬁ-
cantly increased risk of ST (p= 0.02) as compared to cobalt-chromiumTable 4
Patient outcomes at 1-year follow-up.
Stent type Sample size (n) DOCE Cardiac deat
ABSORB II
(2015)
BVS 335 16 (4.8) 0 (0)
EES 166 5 (3.0) 0 (0)
ABSORB Japan
(2015)
BVS 265 11 (4.2) 0 (0)
EES 133 5 (3.8) 0 (0)
BVS-EXAMINATION
(2015)
BVS 290 17 (5.8) 6 (2.1)
EES 290 14 (4.8) 6 (2.1)
ABSORB III
(2015)
BVS 1313 102 (7.8) 8 (0.6)
EES 677 41 (6.1) 1 (0.1)
ABSORB China
(2015)
BVS 238 8 (3.4) 0 (0)
EES 237 10 (4.2) 3 (1.3)
ABSORB Extend
(2015)
BVS 812 41 (5.0) 6 (0.7)
EES 812 38 (4.7) 5 (0.6)
Values are n (%). Abbreviation: BVS: bioresorbable vascular scaffold; DOCE: device-oriented com
ed; TLR: target lesion revascularization; TVR: target vessel revascularization.EES. The two-fold higher rate of ST with BVS, noted in our study, was
similar to previous ﬁndings by Cassese et al. [27] and Lipinski et al.
[28]. Our study also conﬁrmed a signiﬁcantly higher rate of MI associated
with BVS implantation versus DES [28]. Similar to Cassese and colleagues
[27], our study conﬁrmed the known favorable safety proﬁle of the EES. In
addition, at 1-year follow-up, patients with predominantly ACC/AHA
lesion types B or C treated with BVS showed no signiﬁcant difference in
mortality, revascularization rate, or DOCE.
Theoretically, one would expect a reduction in very late stent
thrombosis with BVS after resorption of the polymeric scaffold
after 2 to 3 years. Imaging studies have shown persistent presence
of the BVS at 12 months and bioresorption at 24 to 26 months [2,3,
29]. One of the anticipated beneﬁts of BVS is minimization of very
late stent thrombosis, which occurs after complete bioresorption of
the vascular scaffold and return of normal vessel function [3]. In cohort
A of the ABSORB trial, there was no reported stent thrombosis at 3-year
follow-up although at 2 and 3 years only a single patient was on dual
anti-platelet therapy (i.e. aspirin plus thienopyridine) [30]. After
2 years, optical coherence tomography (OCT) assessment of the BVS
in the ABSORB cohort A showed that the polymeric struts were no
longer recognizable, and on angiography there was very late lumen
enlargement [30]. Similarly, the ABSORB trial cohort B showed at
2-year follow-up no scaffold thrombosis, a return of vasomotion,
and very late lumen enlargement [7].
There are various factors thatmay have contributed to the higher in-
cidence of device thrombosis up to 12-months in patients treated with
BVS versus EES, as seen in the current meta-analysis: The thicker struts
of the BVS may trigger platelet aggregation [31]. Moreover, the lower
ﬁnal in-device minimum lumen diameter achieved with BVS when
compared to EES, may have contributed to the increased thrombotic
risk. Suboptimal implantation may result in device malapposition and
underexpansion, which are known to affect coronary ﬂow pattern and
may subsequently activate the thrombotic cascade [12,32,33]. Well-
controlled post-dilatation and overexpansion of BVS is likely to prevent
a substantial proportion of potential coronary thromboses by improving
the apposition of the scaffold to the vessel wall; on the other hand,
excessive overexpansion can lead to fractures of the polymeric BVS
that may induce thrombus formation [34]. Late scaffold recoil, which
may occur more frequently in the absence of adequate lesion prepara-
tion, has also been associated with BVS thrombosis [35].
Further potential mechanisms for very late BVS thrombosis
include the presence of uncovered BVS struts after 12 months with
discontinuation of dual antiplatelet therapy [32,36]. In our present
analysis, slightly more than 80% of patients were on dual antiplatelet
therapy at 12-month follow-up. Despite the relatively low rates of
BVS thrombosis beyond 12 months, it may be considered to continue
dual antiplatelet therapy until the polymeric scaffold is expected toh MI (target vessel) ID-TLR ID-TVR Scaffold/stent thrombosis*
15 (4.5) 4 (1.2) 6 (1.8) 3 (0.9)
2 (1.2) 3 (1.8) 6 (3.6) 0 (0)
9 (3.4) 7 (2.6) 13 (4.9) 4 (1.5)
3 (2.3) 3 (2.3) 5 (3.8) 2 (1.5)
6 (2.1) 5 (1.7) NR 7 (2.4)
4 (1.4) 4 (1.4) NR 4 (1.4)
79 (6.0) 40 (3.0) 66 (5.0) 20 (1.5)
31 (4.6) 17 (2.5) 25 (3.7) 5 (0.7)
4 (1.7) 6 (2.5) 7 (2.9) 1 (0.4)
2 (0.8) 7 (3.0) 9 (3.8) 0 (0)
27 (3.3) 19 (2.3) NR 8 (1.0)
12 (1.5) 24 (3.0) NR 2 (0.3)
posite endpoint; EES: everolimus-eluting stent; MI:myocardial infarction; NR: not report-
Fig. 3.Meta-analysis comparing 1-year clinical outcomes of patients treated with Absorb
BVS vs. EES (panes A–F) A: device-oriented composite endpoint; B: cardiac death; C:
target vessel myocardial infarction; D: target lesion revascularization; E: target vessel
revascularization; F: deﬁnite-or-probable scaffold/stent thrombosis. Abbreviations: BVS:
bioresorbable vascular scaffold; EES: durable-polymer everolimus-eluting stent.
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might be particularly useful in patients or procedural results with
increased thrombotic risk (e.g. diabetics, patients with renal failure,
overlapping BVS). Finally, late scaffold discontinuity may cause
dislocation of strut remnants into the coronary lumen, which may
result in ﬂow disturbance and shear stress to the vessel wall with
subsequent platelet recruitment and thrombus formation [36].
5. Study limitations
In thismeta-analysis, we used 4 randomized clinical trials in combina-
tion with 2 observational studies to detect differences between Absorb
BVS and EES; nevertheless, both observation studies used propensity
score matching, and as such meaningful comparisons could be made.
While a respectable number of patients (n = 5588) were included in
this meta-analysis, it may still be too few to assess true differences in
the occurrence of rare adverse events such as stent thrombosis. The BVS
technology is still relative new, and as such, from several randomized
trials only 12-month outcome data is available. As a consequence, more
data on a longer follow-up are required to assess the long-term safety
and efﬁcacy of BVS beyond the ﬁrst year after treatment.
6. Conclusion
During the ﬁrst year of follow-up, treatment with everolimus-
eluting BVS was associated with a higher incidence of target vessel MI
and scaffold thrombosis as compared tometallic EES, but the composite
endpoint DOCE showed no signiﬁcant difference between groups. As
BVS may pay off beyond the follow-up period of 1-year, additional
robust data on long-term clinical outcome will be of paramount
importance.
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